Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Calypte Biomedical Corporation (CALY) -- Ignore unavailable to you. Want to Upgrade?

To: Keiko who wrote (214)	11/28/1997 9:17:00 AM
From: JanyBlueEyes	Read Replies (1) \| Respond to of 381

Trinity / Calypte From exchange2000.com : Trinity Biotech Announces Collaboration with Calypte..... Jan 29, 1997....Trinity Biotech announced it had signed an agreement with Calypte Biomedical to develop the world's first one-step urine based HIV test. The first phase of the project will investigate the feasibility of developing a urine - based one- step HIV test utililizing Trinity's Unigold format. From the Trinity Website: Uni-Gold In July 1996, Trinity launched two Uni-Gold tests, for HIV and Hepatitis B, at the American Association of Clinical Chemistry meeting in Chicago. These tests are unique in that they require the addition of just one drop of blood, serum or plasma to the test device to determine the HIV or Hepatitis B status of a patient. The crucial difference between Uni-Gold and existing rapid tests on the market (including Trinity's SeroCard) is that the number of steps to obtain a result is reduced from 7 to 1. This development should enable Trinity to take a major market share in the existing clinical laboratory rapid test market. However, most importantly, the availability for the first time of a simple easy-to-use, one-step whole blood test will open up a potentially huge new market at the POC and OTC level. Trinity has commenced marketing both products through its existing distributor network and is seeking product approval on a country by country basis. The first orders for these products have been received for shipment to customers in the Middle East and Africa. ......In December 1996 Trinity submitted its Uni-Gold HIV test to the Food and Drug Administration (FDA) for approval for use in the POC market....... .....Uni-Gold is an enabling technology - a diagnostic platform suitable for many tests. Trinity's first tests utilising this platform are Uni-Gold HIV and Hepatitis B. We are currently expanding our Uni-Gold product line across a range of infectious diseases and other markers. The range of new Uni-Gold tests will ensure success in existing clinical laboratory markets and create substantial new opportunities in the POC and OTC markets.